A replication-defective human cytomegalovirus vaccine for prevention of congenital infection

Science Translational Medicine

Volumn 8, Issue 362, 2016, Pages

  Wang, Dai ^a   Freed, Daniel C ^a   He, Xi ^a   Li, Fengsheng ^a   Tang, Aimin ^a   Cox, Kara S ^a   Dubey, Sheri A ^a   Cole, Suzanne ^a,b   Medi, Muneeswara Babu ^a   Liu, Yaping ^a   Xu, Jingyuan ^a   Zhang, Zhi Qiang ^a   Finnefrock, Adam C ^a,c   Song, Liping ^a   Espeseth, Amy S ^a   Shiver, John W ^a,d   Casimiro, Danilo R ^a,e   Fu, Tong Ming ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Plasmon Analytics LLC   (United States)

^d SANOFI PASTEUR   (France)

^e AERAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL COMPOUND; CYTOMEGALOVIRUS VACCINE; GH PROTEIN; GL PROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; PUL128 131 PROTEIN; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS ANTIGEN; GAMMA INTERFERON; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONGENITAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA MODIFICATION; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; PROTEIN STABILITY; REGULATORY MECHANISM; VACCINE PRODUCTION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; HUMAN; IMMUNOLOGY; LEPORIDAE; PREGNANCY; PREVENTION AND CONTROL; VACCINE IMMUNOGENICITY; VERTICAL TRANSMISSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; PREGNANCY; RABBITS; VACCINES, ATTENUATED; VIRAL PROTEINS;

EID: 84994037030     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf9387     Document Type: Article

References (52)

1. E. S. Mocarski, T. Shenk, P. D. Griffiths, R. F. Pass, in Fields Virology, D. M. Knipe, P. M. Howley, Eds. (Lippincott Williams & Wilkins, 2013), pp. 1960-2014.
2. M. Boeckh, Complications, diagnosis, management, and prevention of CMV infections: Current and future. Hematology Am. Soc. Hematol. Educ. Program 2011, 305-309 (2011).
3. P. Ramanan, R. R. Razonable, Cytomegalovirus infections in solid organ transplantation: A review. Infect. Chemother. 45, 260-271 (2013).
4. R. F. Pass, Cytomegalovirus infection. Pediatr. Rev. 23, 163-170 (2002).
5. M. R. Schleiss, Cytomegalovirus in the neonate: Immune correlates of infection and protection. Clin. Dev. Immunol. 2013, 501801 (2013).
6. J. F. Modlin, A. M. Arvin, P. Fast, M. Myers, S. Plotkin, R. Rabinovich; National Vaccine Advisory Committee, Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39, 233-239 (2004).
7. K. B. Fowler, S. Stagno, R. F. Pass, Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289, 1008-1011 (2003).
8. K. B. Fowler, S. Stagno, R. F. Pass, W. J. Britt, T. J. Boll, C. A. Alford, The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326, 663-667 (1992).
9. A. W. Sylwester, B. L. Mitchell, J. B. Edgar, C. Taormina, C. Pelte, F. Ruchti, P. R. Sleath, K. H. Grabstein, N. A. Hosken, F. Kern, J. A. Nelson, L. J. Picker, Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202, 673-685 (2005).
10. L. Hertel, Human cytomegalovirus tropism for mucosal myeloid dendritic cells. Rev. Med. Virol. 24, 379-395 (2014).
11. M. G. Revello, C. Fornara, A. Arossa, P. Zelini, D. Lilleri, Role of human cytomegalovirus (HCMV)-specific antibody in HCMV-infected pregnant women. Early Hum. Dev. 90 (Suppl. 1), S32-S34 (2014).
12. W. J. Britt, L. Vugler, E. J. Butfiloski, E. B. Stephens, Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64, 1079-1085 (1990).
13. F. Chiuppesi, F. Wussow, E. Johnson, C. Bian, M. Zhuo, A. Rajakumar, P. A. Barry, W. J. Britt, R. Chakraborty, D. J. Diamond, Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH/gL pentamer potently block primary cytotrophoblast infection. J. Virol. 89, 11884-11898 (2015).
14. A. E. Fouts, P. Chan, J.-P. Stephan, R. Vandlen, B. Feierbach, Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J. Virol. 86, 7444-7447 (2012).
15. S. D. Elek, H. Stern, Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 303, 1-5 (1974).
16. S. A. Plotkin, T. Furukawa, N. Zygraich, C. Huygelen, Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 12, 521-527 (1975).
17. B. J. Neff, R. E. Weibel, E. B. Buynak, A. A. McLean, M. R. Hilleman, Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc. Soc. Exp. Biol. Med. 160, 32-37 (1979).
18. S. A. Plotkin, R. Higgins, J. B. Kurtz, P. J. Morris, D. A. Campbell Jr., T. C. Shope, S. A. Spector, W. M. Dankner, Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58, 1176-1178 (1994).
19. S. A. Plotkin, S. E. Starr, H. M. Friedman, K. Brayman, S. Harris, S. Jackson, N. B. Tustin, R. Grossman, D. Dafoe, C. Barker, Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: A controlled trial. Ann. Intern. Med. 114, 525-531 (1991).
20. S. P. Adler, S. E. Starr, S. A. Plotkin, S. H. Hempfling, J. Buis, M. L. Manning, A. M. Best, Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 171, 26-32 (1995).
21. S. A. Plotkin, S. E. Starr, H. M. Friedman, E. Gönczöl, R. E. Weibel, Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis. 159, 860-865 (1989).
22. X. Cui, B. P. Meza, S. P. Adler, M. A. McVoy, Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26, 5760-5766 (2008).
23. D. Wang, T. Shenk, Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. U.S.A. 102, 18153-18158 (2005).
24. G. Hahn, M. G. Revello, M. Patrone, E. Percivalle, G. Campanini, A. Sarasini, M. Wagner, A. Gallina, G. Milanesi, U. Koszinowski, F. Baldanti, G. Gerna, Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78, 10023-10033 (2004).
25. D. Wang, T. Shenk, Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 79, 10330-10338 (2005).
26. W. Wang, S. L. Taylor, S. A. Leisenfelder, R. Morton, J. F. Moffat, S. Smirnov, H. Zhu, Human cytomegalovirus genes in the 15-kilobase region are required for viral replication in implanted human tissues in SCID mice. J. Virol. 79, 2115-2123 (2005).
27. T.-M. Fu, D. Wang, D. C. Freed, A. Tang, F. Li, X. He, S. Cole, S. Dubey, A. C. Finnefrock, J. ter Meulen, J. W. Shiver, D. R. Casimiro, Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 30, 7469-7474 (2012).
28. L. A. Banaszynski, L.-c. Chen, L. A. Maynard-Smith, A. G. L. Ooi, T. J. Wandless, A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995-1004 (2006).
29. M. Glaß, A. Busche, K. Wagner, M. Messerle, E. M. Borst, Conditional and reversible disruption of essential herpesvirus proteins. Nat. Methods 6, 577-579 (2009).
30. T. Clackson, W. Yang, L. W. Rozamus, M. Hatada, J. F. Amara, C. T. Rollins, L. F. Stevenson, S. R. Magari, S. A. Wood, N. L. Courage, X. Lu, F. Cerasoli Jr., M. Gilman, D. A. Holt, Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl. Acad. Sci. U.S.A. 95, 10437-10442 (1998).
31. T.-A. Cha, E. Tom, G. W. Kemble, G. M. Duke, E. S. Mocarski, R. R. Spaete, Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70, 78-83 (1996).
32. E. Murphy, D. Yu, J. Grimwood, J. Schmutz, M. Dickson, M. A. Jarvis, G. Hahn, J. A. Nelson, R. M. Myers, T. E. Shenk, Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. U.S.A. 100, 14976-14981 (2003).
33. A. J. Bradley, N. S. Lurain, P. Ghazal, U. Trivedi, C. Cunningham, K. Baluchova, D. Gatherer, G. W. G. Wilkinson, D. J. Dargan, A. J. Davison, High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J. Gen. Virol. 90, 2375-2380 (2009).
34. C. E. Patterson, T. Shenk, Human cytomegalovirus UL36 protein is dispensable for viral replication in cultured cells. J. Virol. 73, 7126-7131 (1999).
35. D. Yu, G. A. Smith, L. W. Enquist, T. Shenk, Construction of a self-excisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene. J. Virol. 76, 2316-2328 (2002).
36. S. M. Varnum, D. N. Streblow, M. E. Monroe, P. Smith, K. J. Auberry, L. Paša-Tolić, D. Wang, D. G. Camp II, K. Rodland, S. Wiley, W. Britt, T. Shenk, R. D. Smith, J. A. Nelson, Identification of proteins in human cytomegalovirus (HCMV) particles: The HCMV proteome. J. Virol. 78, 10960-10966 (2004).
37. A. B. Morelli, D. Becher, S. Koernig, A. Silva, D. Drane, E. Maraskovsky, ISCOMATRIX: A novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J. Med. Microbiol. 61, 935-943 (2012).
38. D. Wang, F. Li, D. C. Freed, A. C. Finnefrock, A. Tang, S. N. Grimes, D. R. Casimiro, T.-M. Fu, Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 29, 9075-9080 (2011).
39. P. D. Griffiths, A. Stanton, E. McCarrell, C. Smith, M. Osman, M. Harber, A. Davenport, G. Jones, D. C. Wheeler, J. O'Beirne, D. Thorburn, D. Patch, C. E. Atkinson, S. Pichon, P. Sweny, M. Lanzman, E. Woodford, E. Rothwell, N. Old, R. Kinyanjui, T. Haque, S. Atabani, S. Luck, S. Prideaux, R. S. B. Milne, V. C. Emery, A. K. Burroughs, Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 377, 1256-1263 (2011).
40. Prograf® Prescription Information (Astellas Pharma US, 2015).
41. D. Lilleri, C. Fornara, M. Furione, M. Zavattoni,M. G. Revello, G. Gerna,Development of human cytomegalovirus-Specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J. Infect. Dis. 195, 1062-1070 (2007).
42. D. Lilleri, A. Kabanova, M. G. Revello, E. Percivalle, A. Sarasini, E. Genini, F. Sallusto, A. Lanzavecchia, D. Corti, G. Gerna, Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLOS ONE 8, e59863 (2013).
43. C. W. Hiatt, Kinetics of the inactivation of viruses. Bacteriol. Rev. 28, 150-163 (1964).
44. Replicating Vaccines: A New Generation, P. R. Dormitzer, C. W. Mandl, R. Rappuoli, Eds. (Springer, 2011).
45. S. Plotkin, The history of vaccination against cytomegalovirus. Med. Microbiol. Immunol. 204, 247-254 (2015).
46. F. Goodrum, M. Reeves, J. Sinclair, K. High, T. Shenk, Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110, 937-945 (2007).
47. J. M. Brown, H. Kaneshima, E. S. Mocarski, Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. J. Infect. Dis. 171, 1599-1603 (1995).
48. K. Dulal, T. Cheng, L. Yang, W. Wang, Y. Huang, B. Silver, A. Selariu, C. Xie, D. Wang, A. Espeseth, Y. Lin, L. Wen, N. Xia, T.-M. Fu, H. Zhu, Functional analysis of human cytomegalovirus UL/b' region using SCID-hu mousemodel. J. Med. Virol. 88, 1417-1426 (2016).
49. K. L. Oxford, L. Strelow, Y. Yue, W. L. W. Chang, K. A. Schmidt, D. J. Diamond, P. A. Barry, Open reading frames carried on UL/b' are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys. J. Virol. 85, 5105-5114 (2011).
50. S. Warming, N. Costantino, D. L. Court, N. A. Jenkins, N. G. Copeland, Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33, e36 (2005).
51. R. R. Spaete, C. A. Pachl, Polynucleotides Encoding CMV Neutralizing Proteins (Chiron Corporation, 1995).
52. A. Tang, F. Li, D. C. Freed, A. C. Finnefrock, D. R. Casimiro, D. Wang, T.-M. Fu, A novel highthroughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines. Vaccine 29, 8350-8356 (2011).